SCHEMBL5982525

SCHEMBL5982525

CC(C)(C)c1ccc(-c2cccc(C=O)c2O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.46
TLR2 O60603 1/20 0.44
TLR1 Q15399 1/20 0.44
TLR6 Q9Y2C9 1/20 0.44
AR P10275 1/20 0.40
LMNA P02545 2/20 0.38
TYR P14679 1/20 0.38
GPR84 Q9NQS5 1/20 0.37
P4HB P07237 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
NPC1 O15118 1/20 0.37
NR2F2 P24468 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28221241 0.85 LMNA (0.38) ARLMNAGPR84NR1H4KMT2A
SCHEMBL3371015 0.83 XDH (0.47) LMNAGPR84KMT2AMEN1KDM4E
SCHEMBL12074872 0.82 GPR84 (0.38) LMNAGPR84NR1H4KMT2AMEN1
SCHEMBL3966538 0.81 ERN1 (0.50) ERN1TLR2TLR1TLR6AR
SCHEMBL1043113 0.79 ERN1 (0.55) ERN1TLR2TLR1TLR6LMNA
SCHEMBL31364059 0.79 ERN1 (0.55) ERN1TLR2TLR1TLR6LMNA
SCHEMBL5982536 0.78 CA1 (0.49) ERN1TLR2TLR1TLR6LMNA
SCHEMBL6509592 0.78 ERN1 (0.50) ERN1TLR2TLR1TLR6LMNA
SCHEMBL2560945 0.78 ERN1 (0.50) ERN1TLR2TLR1TLR6LMNA
SCHEMBL5735298 0.78 ERN1 (0.52) ERN1TLR2TLR1TLR6TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581527-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-22 EP claimed
US-20060084682-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2006-04-20 US claimed
EP-1581527-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2005-10-05 EP claimed
WO-2004054515-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO claimed
EP-1581527-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-22 EP disclosed
US-20060084682-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2006-04-20 US disclosed
EP-1581527-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2005-10-05 EP disclosed
WO-2004054515-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084682-A1 Thrombopoietin mimetics MPL, THPO, TEK ERN1 3802/4885TLR2 3503/4885TLR1 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.